Concepts (57)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peptidoglycan | 4 | 2018 | 17 | 0.570 |
Why?
|
| Cell Wall | 4 | 2018 | 34 | 0.560 |
Why?
|
| Enterococcus faecalis | 3 | 2018 | 44 | 0.410 |
Why?
|
| Pancreatic Ducts | 1 | 2007 | 21 | 0.280 |
Why?
|
| Catheterization | 1 | 2008 | 233 | 0.270 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2008 | 241 | 0.270 |
Why?
|
| Pancreatitis, Chronic | 1 | 2007 | 68 | 0.270 |
Why?
|
| Crohn Disease | 2 | 2008 | 283 | 0.250 |
Why?
|
| Sweet Syndrome | 1 | 2005 | 11 | 0.240 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2008 | 304 | 0.220 |
Why?
|
| Sjogren's Syndrome | 1 | 2005 | 89 | 0.220 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 1018 | 0.160 |
Why?
|
| Vancomycin | 2 | 2017 | 219 | 0.150 |
Why?
|
| Glycopeptides | 1 | 2017 | 25 | 0.140 |
Why?
|
| Vancomycin-Resistant Enterococci | 1 | 2017 | 4 | 0.140 |
Why?
|
| Uridine Diphosphate N-Acetylmuramic Acid | 1 | 2017 | 2 | 0.140 |
Why?
|
| Biofilms | 1 | 2018 | 92 | 0.140 |
Why?
|
| Lactates | 1 | 2017 | 93 | 0.140 |
Why?
|
| Dipeptides | 1 | 2017 | 56 | 0.130 |
Why?
|
| Alanine | 1 | 2017 | 183 | 0.130 |
Why?
|
| Amino Acids | 1 | 2018 | 664 | 0.120 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2014 | 31 | 0.120 |
Why?
|
| Pyloric Antrum | 1 | 2014 | 64 | 0.120 |
Why?
|
| Stomach Diseases | 1 | 2014 | 57 | 0.110 |
Why?
|
| Staphylococcus aureus | 1 | 2017 | 460 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 2 | 2017 | 2428 | 0.080 |
Why?
|
| Triamcinolone | 1 | 2008 | 14 | 0.080 |
Why?
|
| Intestine, Large | 1 | 2008 | 15 | 0.080 |
Why?
|
| Constriction, Pathologic | 1 | 2008 | 242 | 0.070 |
Why?
|
| Acetylation | 2 | 2018 | 165 | 0.070 |
Why?
|
| Endopeptidases | 2 | 2018 | 114 | 0.070 |
Why?
|
| Intestine, Small | 1 | 2008 | 309 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2008 | 287 | 0.060 |
Why?
|
| Mass Spectrometry | 2 | 2017 | 330 | 0.060 |
Why?
|
| Infliximab | 1 | 2005 | 67 | 0.060 |
Why?
|
| Middle Aged | 4 | 2014 | 26796 | 0.060 |
Why?
|
| Dermatologic Agents | 1 | 2005 | 33 | 0.060 |
Why?
|
| Acute Disease | 1 | 2007 | 1110 | 0.060 |
Why?
|
| Antirheumatic Agents | 1 | 2005 | 125 | 0.050 |
Why?
|
| Adult | 3 | 2008 | 29481 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2008 | 5160 | 0.040 |
Why?
|
| Plankton | 1 | 2018 | 2 | 0.040 |
Why?
|
| Female | 4 | 2014 | 66557 | 0.040 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2018 | 48 | 0.040 |
Why?
|
| Isotope Labeling | 1 | 2018 | 104 | 0.040 |
Why?
|
| Vancomycin Resistance | 1 | 2017 | 21 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2017 | 196 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2017 | 290 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2014 | 123 | 0.030 |
Why?
|
| Humans | 4 | 2014 | 124703 | 0.030 |
Why?
|
| Male | 2 | 2008 | 61264 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1690 | 0.020 |
Why?
|
| Hepatitis C | 1 | 2014 | 366 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2008 | 16325 | 0.020 |
Why?
|
| Adolescent | 1 | 2008 | 19278 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 1531 | 0.020 |
Why?
|
| Aged | 1 | 2007 | 19763 | 0.020 |
Why?
|